“Biosimilars”

18 result(s)
Drug Pipeline
Increasing Provider Understanding of Biosimilars with Proactive Outreach
Increasing Provider Understanding of Biosimilars with Proactive Outreach More
Briefing
Specialty
7 Stats That Show What Providers Think About Biosimilars
7 stats that show what providers think about biosimilars More
Briefing
2023 Forum
Drug Pipeline
The Dynamic Biosimilars Market
The Dynamic Biosimilars Market More
Video
A family dog-piles on a dad's back.
Drug Pipeline
Optimizing Treatment for Inflammatory Bowel Disease
New Drugs and Tools to Optimize IBD Treatment More
Briefing
Specialty
The Impact of Autoimmune Conditions on Women
Women are overrepresented among autoimmune patients so may benefit the most from new biosimilar treatments More
Briefing
Specialty
Member Education: How We Help Build Awareness
Supporting members through prescription changes with CVS Health’s many touchpoints, expertise, and data More
Briefing
Drug Pipeline
Biosimilars in the Autoimmune Category
Biosimilars in the Autoimmune Category More
Briefing
Specialty
The First Biosimilar to Humira Is Here. Now What?
The First Biosimilar to Humira Is Here More
Briefing
Drug Pipeline
Keeping an Eye on the Drug Pipeline
New Drugs for Ophthalmic Disorders on the Horizon More
Briefing
Drug Pipeline
Expanding Therapies, Indications and Implications for Payors
2022 Marketplace Outlook: Expanding Therapies, Indications and Implications for Payors More
Briefing